Summary:
- The article discusses the results of a clinical trial for Pfizer's BRAFTOVI and MEKTOVI combination therapy in treating patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
- The trial showed that the combination therapy led to long-term, clinically meaningful responses in these patients, with a median overall survival of over 2 years.
- These findings suggest that the BRAFTOVI and MEKTOVI combination could be an effective treatment option for patients with BRAF V600E-mutant metastatic NSCLC, a rare and aggressive form of lung cancer.